Figure 2
Cumulative incidence of inhibitor development according to cumulative number of factor VIII exposure days for all inhibitors, high-titer, and low-titer inhibitors.
Cumulative incidence of inhibitor development according to cumulative number of factor VIII exposure days for all inhibitors, high-titer, and low-titer inhibitors.
